Last updated on July 2020

A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors


Brief description of study

The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

Clinical Study Identifier: NCT02599324

Find a site near you

Start Over

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Clearview Cancer Institute

Huntsville, AL United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

Wake Forest Baptist Health

Winston-Salem, NC United States
  Connect »

Horizon Oncology Research, Inc

Lafayette, IN United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

University of Southern California

Los Angeles, CA United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

St. Mary's Medical Center

San Francisco, CA United States
  Connect »

UCLA

Santa Monica, CA United States
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

San Juan Oncology Associates

Farmington, NM United States
  Connect »

Virginia Cancer Specialists

Fairfax, VA United States
  Connect »

St. Helena Hospital

Saint Helena, CA United States
  Connect »

St. Joseph Health

Santa Rosa, CA United States
  Connect »

Central Care Cancer Center

Bolivar, MO United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.